Khaitan & Co Advised Capital 2B Fund 1, Kotak Lifesciences Fund, And Shastra VC on USD 12 Million Investment In Avammune Biosciences

Khaitan & Co advised Capital 2B Fund 1, Kotak Lifesciences Fund, and Shastra VC on USD 12 million investment in Avammune Biosciences

Khaitan & Co advised lead investors Capital 2B Fund 1, Kotak Lifesciences Fund, and Shastra VC on the proposed USD 12 million investment in Avammune Therapeutics and its subsidiary Avammune Lifesciences.

IvyCap Ventures also joined the round alongside existing investor 1Crowd.

The fresh capital will be used to accelerate Avammune’s proprietary drug pipeline targeting the innate immune system, particularly in the development of orally bioavailable small molecules.

The Khaitan & Co team advising the lead investors was led by Sanchit Agarwal (Partner), Pulkit Chaturvedi (Principal Associate), and Prerna Kapur (Senior Associate), with support on due diligence from Nirupam Lodha (Partner), Abhimanyu Pal (Counsel), Ajeta Anand (Senior Associate), Chirag Mangal (Senior Associate), Malika Nandkeolyar (Senior Associate), and Vanshika Thapliyal (Associate).

IvyCap Ventures was also represented by Khaitan & Co, with the team led by Karthika Ravi Menon (Partner) and Pathlavath Digvijay Naik (Senior Associate) from the firm’s Chennai office.

Click to know more about khaitan & Co

If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at [email protected] or call us on +91 8879634922.